The severity of systemic lupus erythematosus negatively correlates with the increasing number of CD4⁺CD25^highFoxP3⁺ regulatory T cells during repeated plasmapheresis treatments of patients

References

• Tsokos GC, Wong HK, Enyedy EJ, Nambiar MP. Immune cell signaling in lupus. Curr Opin Rheumatol 2000; 12: 355–363
   PubMedGoogle Scholar
• Khan IU, Laxminarayana D, Kammer GM. Protein kinase A RIβ subunit deficiency in lupus T lymphocytes: Bypassing a block in RIβ translation reconstitutes protein kinase A activity and augments IL-2 production. J Immunol 2001; 166: 7600–7605
   PubMed Web of Science ®Google Scholar
• Nambiar MP, Enyedy EJ, Warke GV, Krishnan S, Dennis G, Wong KH, et al. T cell signaling abnormalities in systemic lupus erythematosus are associated with increased mutations/polymorphisms and splice variants of T cell receptor ζ chain messenger RNA. Arthritis Rheum 2001; 44: 1336–1350
   PubMed Web of Science ®Google Scholar
• Liossis SN, Kovacs B, Dennis G, Kammer GM, Tsokos GC. B cells from patients with systemic lupus erythematosus display abnormal antigen receptor-mediated early signal transduction events. J Clin Invest 1996; 98: 2549–2557
   PubMed Web of Science ®Google Scholar
• Steinbach F, Henke F, Krause B, Thiele B, Burmester GR, Hiepe F. Monocytes from systemic lupus erythematosus patients are severely altered in phenotype and lineage flexibility. Ann Rheum Dis 2000; 59: 283–288
   PubMed Web of Science ®Google Scholar
• Sipka S, Szanto S, Szucs K, Kovacs I, Kiss E, Antal-Szalmas P, et al. Decreased arachidonic acid release in peripheral blood monocytes of patients with systemic lupus erythematosus. J Rheumatol 2001; 28: 2012–2017
   PubMedGoogle Scholar
• Biro T, Griger Z, Kiss E, Papp H, Aleksza M, Kovacs I, Zeher M, Bodolay E, Csepany T, Szucs K, Gergely P, Kovacs L, Szegedi G, Sipka S. Abnormal cell-specific expressions of certain protein kinase C isoenzymes in peripheral mononuclear cells of patients with systemic lupus erythematosus: Effect of corticosteroid application. Scand J Immunol. 2004; 60(4)421–428
   PubMedGoogle Scholar
• Crispin JC, Martinez A, Alococer-Varela J. Quantification of regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun 2003; 21: 273–276
   PubMed Web of Science ®Google Scholar
• Liu MF, Wang CR, Fung LL, Wu CR. Decreased CD4+CD25+T cells in peripheral blood of patients with systemic lupus erythematosus. Scand J Immunol 2004; 59: 198–202
   PubMed Web of Science ®Google Scholar
• Valencia X, Yarboro C, Illei G, Lipsky PE. Deficient CD4+CD25high T regulatory cell function in patients with active and inactive systemic lupus erythematosus. J Immunol 2007; 178(4)2579–2588
   PubMed Web of Science ®Google Scholar
• Shevach EM. Certified Professionals: CD4+CD25+ suppressor T Cells. J Exp Med 2001; 193: F41–F46
   PubMed Web of Science ®Google Scholar
• Maloy JK, Powrie F. Regulatory cells in the control of immune pathology. Nat Immunol 2001; 2: 816–822
   PubMed Web of Science ®Google Scholar
• Salomon B, Lenschow DJ, Rhee L, Ashourian N, Singh B, Sharpe A, et al. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 2000; 12: 431–440
   PubMed Web of Science ®Google Scholar
• Hara M, Kingsley CI, Niimi M, Read S, Turvey SE, Bushell AR, et al. IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo. J Immunol 2001; 166: 3789–3796
   PubMed Web of Science ®Google Scholar
• Gao Q, Rouse TM, Kazmerzak K, Field EH. CD4+CD25+ cells regulate CD8 cell anergy in neonatal tolerant mice. Transplantation 1999; 68: 1891–1897
   PubMedGoogle Scholar
• Taylor PA, Noelle RJ, Blazar BR. CD4+CD25+ immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade. J Exp Med 2001; 193: 1311–1318
   PubMed Web of Science ®Google Scholar
• Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: Common basis between tumour immunity and autoimmunity. Immunol 1999; 163: 5211–5218
   Google Scholar
• Annacker O, Pimenta-Araujo R, Burlen-Defranour O, Barbosa TC, Cumano A, Bandeira A. CD25+CD4+ T cells regulate the expansion of peripheral CD4 T cells through the production of IL-10. J Immunol 2001; 166: 3008–3018
   PubMed Web of Science ®Google Scholar
• Baecher-Allan C, Brown J, Freeman GJ, Hafler DA. CD4+CD25high regulatory cells in human peripheral blood. J Immunol 2001; 167: 1245–1253
   PubMed Web of Science ®Google Scholar
• Hashimoto H, Yano T, Kawanishi T, Tsuda H, Nagasawa T. Outcome of collagen vascular diseases by treatment with plasmapheresis. Ther Apher 1998; 2: 268–272
   PubMedGoogle Scholar
• Soltész P, Aleksza M, Antal-Szalmás P, Lakos G, Szegedi G, Kiss E. Plasmapheresis modulates TH1/TH2 imbalance in patients with systemic lupus erythematosus according to measurement of intracytoplasmatic cytokines. Autoimmunity 2002; 35: 51–56
   PubMed Web of Science ®Google Scholar
• Hanly JG, Hong C, Zayed E, Jones JV, Jones E. Immunomodulating effects of synchronised plasmapheresis and intravenous bolus cyclophosphamide in systemic lupus erythemathosus. Lupus 1995; 4: 457–463
   PubMed Web of Science ®Google Scholar
• Erickson RW, Franklin WA, Emlen W. Treatment of haemorrhagic lupus pneumonitis with plasmapheresis. Semin Arthritis Rheum 1994; 24: 114–123
   PubMed Web of Science ®Google Scholar
• Wallace DJ. Systemic lupus erythematosus. Drugs Today (Barc) 2002; 38: 259–263
   PubMedGoogle Scholar
• Dau PC, Callahan J, Parker R, Golbus J. Immunologic effects of plasmapheresis synchronised with pulse cyclophosphamide in systemic lupus erythematosus. J Rheumatol 1991; 18: 270–276
   PubMed Web of Science ®Google Scholar
• Jones JV, Robinson MF, Parcinay RK, Layter LF, McLeod B. Therapeutic plasmapheresis in systemic lupus erythematosus: Effect on immune complexes and antibodies to DNA. Arthritis Rheum 1981; 24: 1113–1120
   PubMedGoogle Scholar
• Csípő I, Kiss E, Soltész P, Antal-Szalmás P, Szegedi G, Cohen JHM, et al. Effect of plasmapheresis on ligand binding capacity and expression of erythrocyte complement receptor type 1 (CR1) of patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 1999; 118: 458–464
   PubMedGoogle Scholar
• Csípő I, Kávai M, Kiss E, Bedő Z, Csongor J, Szegedi G, et al. Serum complement activation of SLE patients during plasmapheresis. Autoimmunity 1997; 25: 139–146
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Lan SP, Rohde RD, Lachin J. A controlled trial of plasmapheresis theraphy in severe lupus nephritis. N Engl J Med 1992; 326: 1373–1379
   PubMed Web of Science ®Google Scholar
• Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725
   PubMed Web of Science ®Google Scholar
• Bombardier C, Gladman D, Urowitz M, Caron D, Chang C, and the Committee on Prognosis Studies in SLE. Derivation of SLEDAI. A disease activity index for lupus patients. Arthritis Rheum 1992; 35: 630–640
   PubMed Web of Science ®Google Scholar
• Kamphuis E, Junt T, Waibler Z, Forster R, Kalinke U. Type I interferons directly regulate lymphocyte recirculation and cause transient blood lymphopenia. Blood 2006; 108(10)3253–3261
   PubMed Web of Science ®Google Scholar
• Blum KS, Pabst R. Lymphocyte numbers and subsets in the human blood. Do they mirror the situation in all organs?. Immunol Lett 2007; 108: 45–51
   PubMed Web of Science ®Google Scholar
• Harada T, Ozono Y, Miyazaki M, Sasaki O, Miyazaki K, Abe K, et al. Plasmapheresis in the treatment of rapidly progressive glomerulonephritis. Ther Apher 1997; 1: 336–339
   PubMedGoogle Scholar
• Asherson RA, Cervera R, Piette JC, Font J, Lie JT, Burcoglu A, et al. Catastrofic antiphospholipid syndrome. Clinical and laboratory features of 50 patients. Medicine (Baltimore) 1998; 77: 195–207
   PubMed Web of Science ®Google Scholar
• Karagiannidis C, Akdis M, Holopainen P, Woolley NJ, Hense G, Rückert B, et al. Glucocorticoids upregulate FOXP3 expression and regulatory T cells in asthma. J Allergy Clin Immunol 2004; 114: 1425–1433
   PubMed Web of Science ®Google Scholar
• Lohr J, Knoechel B, Wang JJ, Villarino VA, Abbas KA. Role of IL-17 and regulatory T lymphocytes in a systemic autoimmune disease. JEM 2006; 203: 2785–2791
   PubMed Web of Science ®Google Scholar
• Korn T, Bettelli E, Gao W, Awasthi A, Jager A, Strom TB, Oukka M, Kuchroo VK. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 2007, DOI 10.1038
   Google Scholar